306 related articles for article (PubMed ID: 25623164)
1. Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment.
Zippelius A; Schreiner J; Herzig P; Müller P
Cancer Immunol Res; 2015 Mar; 3(3):236-44. PubMed ID: 25623164
[TBL] [Abstract][Full Text] [Related]
2. Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model.
Luheshi NM; Coates-Ulrichsen J; Harper J; Mullins S; Sulikowski MG; Martin P; Brown L; Lewis A; Davies G; Morrow M; Wilkinson RW
Oncotarget; 2016 Apr; 7(14):18508-20. PubMed ID: 26918344
[TBL] [Abstract][Full Text] [Related]
3. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.
Liu L; Mayes PA; Eastman S; Shi H; Yadavilli S; Zhang T; Yang J; Seestaller-Wehr L; Zhang SY; Hopson C; Tsvetkov L; Jing J; Zhang S; Smothers J; Hoos A
Clin Cancer Res; 2015 Apr; 21(7):1639-51. PubMed ID: 25589619
[TBL] [Abstract][Full Text] [Related]
4. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
5. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
6. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
[TBL] [Abstract][Full Text] [Related]
7. PD-L1/PD-1 signal deficiency promotes allogeneic immune responses and accelerates heart allograft rejection.
Wang W; Carper K; Malone F; Latchman Y; Perkins J; Fu Y; Reyes J; Li W
Transplantation; 2008 Sep; 86(6):836-44. PubMed ID: 18813109
[TBL] [Abstract][Full Text] [Related]
8. Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor.
Prosser ME; Brown CE; Shami AF; Forman SJ; Jensen MC
Mol Immunol; 2012 Jul; 51(3-4):263-72. PubMed ID: 22503210
[TBL] [Abstract][Full Text] [Related]
9. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.
Abiko K; Matsumura N; Hamanishi J; Horikawa N; Murakami R; Yamaguchi K; Yoshioka Y; Baba T; Konishi I; Mandai M
Br J Cancer; 2015 Apr; 112(9):1501-9. PubMed ID: 25867264
[TBL] [Abstract][Full Text] [Related]
10. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
Mangsbo SM; Sandin LC; Anger K; Korman AJ; Loskog A; Tötterman TH
J Immunother; 2010 Apr; 33(3):225-35. PubMed ID: 20445343
[TBL] [Abstract][Full Text] [Related]
11. Synergistic CD40 signaling on APCs and CD8 T cells drives efficient CD8 response and memory differentiation.
Meunier S; Rapetti L; Beziaud L; Pontoux C; Legrand A; Tanchot C
J Leukoc Biol; 2012 Jun; 91(6):859-69. PubMed ID: 22241832
[TBL] [Abstract][Full Text] [Related]
12. Different costimulation signals used by CD4(+) and CD8(+) cells that independently initiate rejection of allogenic hepatocytes in mice.
Gao D; Li J; Orosz CG; Bumgardner GL
Hepatology; 2000 Nov; 32(5):1018-28. PubMed ID: 11050052
[TBL] [Abstract][Full Text] [Related]
13. Reduced tumor-antigen density leads to PD-1/PD-L1-mediated impairment of partially exhausted CD8⁺ T cells.
Kaiser AD; Schuster K; Gadiot J; Borkner L; Daebritz H; Schmitt C; Andreesen R; Blank C
Eur J Immunol; 2012 Mar; 42(3):662-71. PubMed ID: 22144176
[TBL] [Abstract][Full Text] [Related]
14. Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses.
Beavis PA; Milenkovski N; Henderson MA; John LB; Allard B; Loi S; Kershaw MH; Stagg J; Darcy PK
Cancer Immunol Res; 2015 May; 3(5):506-17. PubMed ID: 25672397
[TBL] [Abstract][Full Text] [Related]
15. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.
Stewart R; Morrow M; Hammond SA; Mulgrew K; Marcus D; Poon E; Watkins A; Mullins S; Chodorge M; Andrews J; Bannister D; Dick E; Crawford N; Parmentier J; Alimzhanov M; Babcook JS; Foltz IN; Buchanan A; Bedian V; Wilkinson RW; McCourt M
Cancer Immunol Res; 2015 Sep; 3(9):1052-62. PubMed ID: 25943534
[TBL] [Abstract][Full Text] [Related]
16. CD4 T Cell Depletion Substantially Augments the Rescue Potential of PD-L1 Blockade for Deeply Exhausted CD8 T Cells.
Penaloza-MacMaster P; Provine NM; Blass E; Barouch DH
J Immunol; 2015 Aug; 195(3):1054-63. PubMed ID: 26116499
[TBL] [Abstract][Full Text] [Related]
17. Anti-PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment.
Xiong H; Mittman S; Rodriguez R; Moskalenko M; Pacheco-Sanchez P; Yang Y; Nickles D; Cubas R
Cancer Res; 2019 Apr; 79(7):1493-1506. PubMed ID: 30679180
[TBL] [Abstract][Full Text] [Related]
18. Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.
Homet Moreno B; Zaretsky JM; Garcia-Diaz A; Tsoi J; Parisi G; Robert L; Meeth K; Ndoye A; Bosenberg M; Weeraratna AT; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Ribas A
Cancer Immunol Res; 2016 Oct; 4(10):845-857. PubMed ID: 27589875
[TBL] [Abstract][Full Text] [Related]
19. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells.
Latchman YE; Liang SC; Wu Y; Chernova T; Sobel RA; Klemm M; Kuchroo VK; Freeman GJ; Sharpe AH
Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10691-6. PubMed ID: 15249675
[TBL] [Abstract][Full Text] [Related]
20. Cutting edge: identification of autoreactive CD4+ and CD8+ T cell subsets resistant to PD-1 pathway blockade.
Pauken KE; Nelson CE; Martinov T; Spanier JA; Heffernan JR; Sahli NL; Quarnstrom CF; Osum KC; Schenkel JM; Jenkins MK; Blazar BR; Vezys V; Fife BT
J Immunol; 2015 Apr; 194(8):3551-3555. PubMed ID: 25769925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]